Fam Pract. 1987 Sep;25(3):251-6. \[[PubMed: 3625141](https://pubmed.ncbi.nlm.nih.gov/3625141)\] 25. Smucny J, Becker L, Glazier R. Beta2-agonists for acute bronchitis. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001726. \[[PubMed: 17054140](https://pubmed.ncbi.nlm.nih.gov/17054140)\] 26. Becker LA, Hom J, Villasis-Keever M, van der Wouden JC. Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. Cochrane Database Syst Rev. 2015 Sep 03;2015(9):CD001726. \[[PMC free article: PMC7078572](/pmc/articles/PMC7078572/)\] \[[PubMed: 26333656](https://pubmed.ncbi.nlm.nih.gov/26333656)\] 27. Smith DRM, Dolk FCK, Pouwels KB, Christie M, Robotham JV, Smieszek T. Defining the appropriateness and inappropriateness of antibiotic prescribing in primary care. J Antimicrob Chemother. 2018 Feb 01;73(suppl_2):ii11-ii18. \[[PMC free article: PMC5890733](/pmc/articles/PMC5890733/)\] \[[PubMed: 29490061](https://pubmed.ncbi.nlm.nih.gov/29490061)\] 28. Llor C, Bjerrum L. Antibiotic prescribing for acute bronchitis. Expert Rev Anti Infect Ther. 2016 Jul;14(7):633-42. \[[PubMed: 27219826](https://pubmed.ncbi.nlm.nih.gov/27219826)\] 29. Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD000245. \[[PubMed: 15494994](https://pubmed.ncbi.nlm.nih.gov/15494994)\] 30. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM., EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397-1408. \[[PMC free article: PMC8908851](/pmc/articles/PMC8908851/)\] \[[PubMed: 35172054](https://pubmed.ncbi.nlm.nih.gov/35172054)\] 31. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 18, 2023. Features, Evaluation, and Treatment of Coronavirus (COVID-19) \[[PubMed: 32150360](https://pubmed.ncbi.nlm.nih.gov/32150360)\] 32. Wesolowski A, Miller JL, Shields M, Dela-Pena J. Antimicrobial prescribing after rapid influenza PCR implementation in the emergency department. Am J Emerg Med. 2023 Sep;71:123-128. \[[PubMed: 37390608](https://pubmed.ncbi.nlm.nih.gov/37390608)\] 33. Tejada S, Jansson M, Solé-Lleonart C, Rello J. Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials. Eur J Intern Med. 2021 Apr;86:54-65. \[[PubMed: 33358065](https://pubmed.ncbi.nlm.nih.gov/33358065)\] 34. Ivaska L, Barkoff AM, Mertsola J, He Q. Macrolide Resistance in _Bordetella pertussis_ : Current Situation and Future Challenges. Antibiotics (Basel). 2022 Nov 07;11(11) \[[PMC free article: PMC9686491](/pmc/articles/PMC9686491/)\] \[[PubMed: 36358225](https://pubmed.ncbi.nlm.nih.gov/36358225)\] 35. Tiwari T, Murphy TV, Moran J., National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep. 2005 Dec 09;54(RR-14):1-16. \[[PubMed: 16340941](https://pubmed.ncbi.nlm.nih.gov/16340941)\] 36. Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae outbreak at a university - Georgia, 2012. MMWR Morb Mortal Wkly Rep. 2013 Aug 02;62(30):603-6. \[[PMC free article: PMC4604853](/pmc/articles/PMC4604853/)\] \[[PubMed: 23903594](https://pubmed.ncbi.nlm.nih.gov/23903594)\] 37. Tsiodras S, Kelesidis I, Kelesidis T, Stamboulis E, Giamarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005 Dec;51(5):343-54. \[[PubMed: 16181677](https://pubmed.ncbi.nlm.nih.gov/16181677)\] 38. Baheerathan A,